Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The proposed research project must involve use of PLCO biospecimens and take advantage of the unique characteristics of the PLCO biospecimens. Key aspects of the opportunity include: • The use of PLCO biospecimens to advance research in cancer etiology and early detection biomarkers • The unique characteristics of the PLCO biospecimens, including high-quality, prospectively collected, serial pre-diagnostic blood samples and a one-time collection of buccal cells • The availability of associated data, including demographic, diet, lifestyle, smoking, screening results, and clinical data • The support for a wide range of cancer research, including biochemical and genetic analyses of cancer risk and discovery and validation of early detection biomarkers.